
Venture capital · Growth stage
Biomatics Capital
Seattle-based venture firm focused on healthcare and medicine, backing genomics, therapeutics, diagnostics and digital health companies. It states it is no longer making new investments.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Biomatics Capital right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
Rounds Biomatics Capital joined, from press and the firm’s own posts.
Every round Biomatics Capital joined
Round sizes, Biomatics Capital’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Biomatics Capital backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Biomatics Capital
Events where Biomatics Capital’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Biomatics Capital is based in Seattle, United States.
1 fund vehicle is on public registers (SEC adviser filings), including BIOMATICS CAPITAL PARTNERS, L.P.
Stages: Series B. From the firm’s own website.
The firm believes genomics combined with digital data is enabling better therapeutics, diagnostics and delivery models, moving medicine toward value-based care. It backs outlier, non-incremental companies and acts as an advisor and network builder, sometimes leading rounds and taking board seats. From the firm’s own website.
Biomatics Capital lists 19 portfolio companies on its website, including Alairion, BlackThorn, BlueTalon, Compass and Denali.
Firms whose websites list some of the same companies include ARCH Venture Partners, Decheng Capital and DCVC.
Know before Biomatics Capital’s next round is announced.
PRO tracks Biomatics Capital’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.